stockrowMirum Pharmaceuticals, Inc.
MIRM Healthcare Biotechnology
Mirum Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $521.3 million, up 54.7% from fiscal 2024.
- Revenue
- +39.6%
- EPS
- −1,136.8%
- Free cash flow
- −114.2%
- Total debt
- +136.4%
Quarter to September 2026, against a year earlier
Follow MIRM
Alert me
Mirum Pharmaceuticals, Inc. (MIRM) Book value per share
Mirum Pharmaceuticals, Inc.'s book value per share at the end of fiscal 2025 was 6.3×, up 32.0% from 4.7× in fiscal 2024. At the end of the quarter to 30 September 2026 it was −0.8×. Over the past ten years it has ranged from −19.3× (fiscal 2018) to 11.3× (fiscal 2019); the current reading is higher than 75% of that period. Mirum Pharmaceuticals, Inc. ranks 564th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 6.3× | 32.03% |
| FY2024 | 4.7× | (21.94%) |
| FY2023 | 6.1× | 44.90% |
| FY2022 | 4.2× | 5.87% |
| FY2021 | 4.0× | (41.83%) |
| FY2020 | 6.8× | (39.95%) |
| FY2019 | 11.3× | — |
| FY2018 | −19.3× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | −0.8× | — |
| Jun 2026 | −0.2× | — |
| Mar 2026 | 4.1× | (34.27%) |
| Dec 2025 | 6.3× | 8.70% |
| 29 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | 48.2× |
| BLTE Belite Bio, Inc. Sponsored ADR compare | 19.3× |
| ORKA Oruka Therapeutics, Inc. compare | 17.7× |
| CGON CG Oncology, Inc. compare | 11.7× |
| IMVT Immunovant, Inc. compare | 3.6× |
| IONS Ionis Pharmaceuticals, Inc. compare | 2.7× |
| KOD Kodiak Sciences Inc. compare | 1.0× |
| MIRM Mirum Pharmaceuticals, Inc. | −0.8× |
| PTCT PTC Therapeutics, Inc. compare | −2.3× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on MIRM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement